Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by MaaT Pharma
< Previous
1
2
3
Next >
MaaT Pharma, Leader in Development of Microbiome-Based Therapies in Oncology, Awarded Government Funding for Clinical Development of MaaT033 as part of the France 2030 Plan
November 30, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Provides Third Quarter 2023 Business Update and Reports Financial Results
November 09, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Announces First Patient Dosed in Phase 2b Randomized Clinical Trial Evaluating MaaT033 in Patients Receiving Allo-HSCT
November 06, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Announces Two Poster Presentations for MaaT013 and MaaT033 at the Upcoming ASH Conference
November 02, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma to Present Preclinical Data at SITC on MaaT034, an Artificial Intelligence-Generated Product Aimed at Improving Patients’ Responses to Immunotherapies
October 31, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Announces Positive Outcome Following DSMB Review Reinforcing Confidence in Phase 3 On-Going Trial in Acute Graft-versus-Host Disease with MaaT013
October 26, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Publishes its Half Year 2023 Results and Provides a Business Update
September 26, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma and Skyepharma Complete Construction of Europe’s Largest Manufacturing Facility for Microbiome Ecosystem Therapies
September 12, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Announces European Medicines Agency Granted MaaT033 Orphan Drug Designation aiming to improve overall survival in patients undergoing Hematopoietic Stem Cell transplantation
September 07, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Provides Second Quarter 2023 Business Update and Reports Financial Results
July 27, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Announces Publication of Results in eClinicalMedicine Journal Highlighting Clinical Benefit of MaaT013 in aGvHD
July 26, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Joins Microbiome Therapeutics Innovation Group
July 20, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Announces New Appointments to the Board and Executive Team
June 21, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Announces Cash and Revenues for the First Quarter of 2023
May 09, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease
April 24, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma to Present Clinical Data for MaaT013 and MaaT033 at 49th EBMT Annual Meeting
April 11, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Announces 2022 Annual Results and Provides a Business Overview
March 30, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Receives Two Clinical Trial Application Authorizations to Evaluate MaaT033 in Two Therapeutic Indications in Europe
March 27, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Announces Initiation of Coverage of its Stock by Kepler Cheuvreux
January 27, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Provides Corporate Update and Highlights Key Expected Milestones in 2023
January 24, 2023
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Presents Promising Detailed Results from Completed Phase 1b Trial with MaaT033 at the 64th ASH Annual Meeting
December 11, 2022
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Presents Compelling Consolidated MaaT013 Clinical Data at the 64th ASH Annual Meeting
December 10, 2022
From
MaaT Pharma
Via
Business Wire
MaaT Pharma To Webcast Investor Meeting in Conjunction with ASH 2022 Conference
November 29, 2022
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Reports Cash and Revenues for Third Quarter 2022
November 08, 2022
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Announces Participation in Scientific and Investor Conferences in November
November 07, 2022
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Announces Oral and Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting
November 03, 2022
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Appoints Nathalie Corvaïa as Chief Scientific Officer and Strengthens its R&D Activities in Immuno-Oncology
October 04, 2022
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Publishes its Half Year Results and Provides a Business Overview
September 29, 2022
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Announces Participation in Three Upcoming Investor Conferences in September
September 08, 2022
From
MaaT Pharma
Via
Business Wire
MaaT Pharma Reports Cash and Revenues for Second Quarter 2022
July 28, 2022
From
MaaT Pharma
Via
Business Wire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
